Gibson Dunn Advises Jade Biosciences on Merger with Aerovate Therapeutics, Inc. and Concurrent Private Placement

Firm News  |  October 31, 2024

Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent $300 million private placement of shares of its common stock and pre-funded warrants to a syndicate of healthcare investors.

The Gibson Dunn corporate team includes partners Ryan Murr, Branden Berns and Chris Trester and associates Evan Shepherd and Candice Johnson.